- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Japan Oncology Market – Best in Class Practices for Advancing Patient Outcomes
Japan, the second largest market for branded pharmaceuticals and innovation, is driven in part by Oncology with recent advances in genomic analysis technology. A genetic screening project, LC-SCRUM, conducted by the National Cancer Center, is contributing to the development of multiple novel therapeutics in Japan. Live: Tuesday, Oct. 29, 2019 at 11am JST On demand available after airing until Oct. 29, 2020 Register free
Register free: http://www.pharmexec.com/pe_w/advancing
Event Overview:
Japan is the second largest market for branded pharmaceuticals and innovation. Continuous investment in development in Japan is creating many opportunities and growing the potential for multinational biopharma companies.
This is driven in part by oncology. With recent advances in genomic analysis technology, such as next generation sequencing (NGS), progress is being made in establishing genomic cancer medicine, whereby effective therapies are selected based on the results of genomic analysis of each individual patient.
The National Cancer Center of Japan is conducting a genetic screening project, LC-SCRUM, in cooperation with over 200 medical institutions and pharmaceutical manufacturers across Japan. Since 2013, LC-SCRUM has performed screening of treatment target genes in over 7,000 lung cancer patients and contributed to the development of multiple novel therapeutics in Japan.
In addition, the Japanese market is driven by ongoing regulatory and government initiatives that reward innovation, shifts in population demographics, increased disease awareness, and identifiable patient populations, among other factors.
Join IQVIA Japan as we discuss what is going on, the strong potential outlook, and how opportunities in the market affect your business.
Key Learning Objectives:
How to seize the opportunity in this strong potential market
The contribution of a genetic screening project, LC-SCRUM, by the National Cancer Center, for the development of multiple novel therapies
Overview and changes in the Japanese Regulatory Environment
Speakers: Dr. Koichi Goto, Chief, Department of Thoracic Oncology, National Cancer Center Hospital East
Alan Thomas, Director, Thought Leadership, IQVIA Japan Group
Time and Date: Tuesday, Oct. 29, 2019 at 11am JST
On demand available after airing until Oct. 29, 2020
Sponsor: IQVIA
Register free: http://www.pharmexec.com/pe_w/advancing
